[{"orgOrder":0,"company":"Avance Clinical","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Bugworks","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Bugworks","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BWC0977","moa":"Bacterial topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Spinogenix","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Kither Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Actinogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"iQure Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"iQ-007","moa":"EAAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Vivani Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Implant","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"GRIN Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"GRIN Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor| GRIN1|GRIN2B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Seismic Therapeutic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"S-1117","moa":"IgG","graph1":"Undisclosed","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Seismic Therapeutic","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"S-4321","moa":"PD?1\/c?RIIb","graph1":"Undisclosed","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"ADARx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Clinical \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Inimmune","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INI-4001","moa":"TLR","graph1":"Oncology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Inimmune","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INI-2004","moa":"Toll-like-4 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"SignPath Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tafamidis","moa":"Transthyretin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"BioFactura","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BFI-751","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Parvus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PVT201","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"}]

Find Clinical Drug Pipeline Developments & Deals by Avance Clinical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Tuberous Sclerosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 16, 2025

                          Lead Product(s) : Radiprodil

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I

                          Recipient : GRIN Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberous Sclerosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2025

                          Lead Product(s) : Radiprodil

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase I

                          Recipient : GRIN Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : IQ-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistant Epilepsy.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 27, 2025

                          Lead Product(s) : iQ-007

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : iQure Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : S-4321 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          March 14, 2025

                          Lead Product(s) : S-4321

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Seismic Therapeutic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : S-1117 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : S-1117

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Seismic Therapeutic

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PVT201 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Cirrhosis, Biliary.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : PVT201

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Recipient : Parvus Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : KIT2014 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 26, 2024

                          Lead Product(s) : KIT2014

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Recipient : Kither Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : SPG601 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fragile X Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : SPG601

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Recipient : Spinogenix

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The partnership aims to evaluate Oragenics' lead drug candidate, ONP-002, a NCE delivered through a unique intranasal device, for mild Traumatic Brain Injury.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          May 07, 2024

                          Lead Product(s) : ONP-002

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Recipient : Oragenics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : INI-4001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 08, 2024

                          Lead Product(s) : INI-4001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Inimmune

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank